Barclays Starts Chiasma (CHMA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
William Blair Starts Chiasma (CHMA) at Outperform
August 10, 2015 7:28 AM EDTWilliam Blair initiated coverage on Chiasma (NASDAQ: CHMA) with an Outperform rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Chiasma click here. For more ratings news on Chiasma click here.
Shares of Chiasma closed at $23.83 yesterday.
... MoreCowen Starts Chiasma (CHMA) at Outperform
August 10, 2015 6:25 AM EDTCowen initiates coverage on Chiasma (NASDAQ: CHMA) with a Outperform rating and a price target of $43.00.
Analyst Ritu Baral commented, "We think Chiasma's TPE-Octreotide will become a key acromegaly treatment in the US/EU. We expect FDA to approve TPE-Octreotide in mid 2016,... More
